Biomarker for determining cancer grade, prognosis and / or efficacy of anticancer drug treatment, companion diagnostic drug for selecting anticancer drug, and anticancer drug

摘要

PROBLEM TO BE SOLVED: To provide a biomarker for determining the malignancy of cancer, and the prognosis and/or effectiveness of an anticancer agent treatment, to provide a method for determining, using miR, the malignancy of cancer, and the prognosis and/or effectiveness of the anticancer agent treatment, as well as to provide a companion diagnostic agent or anticancer agent containing miR.SOLUTION: The invention relates to a method of using a biomarker that can determine the malignancy of cancer, and the prognosis and/or the effectiveness of anticancer agent treatment, while considering a patient's immune status, the biomarker being one or more kinds of microRNAs that exhibit a characteristic expression pattern in a patient with an IL-6 high expression level in blood. The invention also relates to a biomarker that can utilize, as anticancer agents, either a specified miR, and an inhibitory nucleic acid against this or a functional equivalent thereof that can inhibit the growth of cancer cells by being introduced into the cancer cells.SELECTED DRAWING: Figure 1